Can I Take Mounjaro With an Underactive Thyroid?

The misconception worth correcting first: an underactive thyroid is not a blanket barrier

A common assumption is that any thyroid condition rules out weight-loss medicines. That is not accurate. The Mounjaro SmPC does not list hypothyroidism as a contraindication. People with well-controlled, medically managed underactive thyroid are regularly assessed for tirzepatide, weight gain is itself one of the recognised consequences of hypothyroidism, so the overlap between these two conditions is common and clinicians are well used to navigating it.

The distinction that matters is between controlled and uncontrolled thyroid disease. If your TSH sits within range on a stable levothyroxine dose, that is a very different starting point from recently diagnosed hypothyroidism or a thyroid that is still being titrated. A prescriber reviewing your case will want to know your current TSH result, your levothyroxine dose, and how long you have been stable, information that takes less than a minute to look up on your last blood test letter before you start your consultation. That preparation genuinely helps.

What does warrant a specific conversation is a personal or family history of medullary thyroid carcinoma, or a condition called MEN2 (multiple endocrine neoplasia type 2). In those situations, tirzepatide is not recommended, based on animal study findings, even though the human evidence remains limited. A broader overview of who Mounjaro is and is not suitable for covers these contraindications in more detail.

How Mounjaro's mechanism interacts with levothyroxine

Tirzepatide works partly by slowing how quickly the stomach empties. That is useful for reducing appetite and managing blood sugar, but it creates a practical question when you also take levothyroxine, a medicine whose absorption depends quite specifically on being taken on an empty stomach, without food or other tablets nearby.

There is no formal drug-interaction designation between tirzepatide and levothyroxine in UK prescribing references, but the NHS and clinical guidelines both note that anything affecting gastric motility can alter levothyroxine absorption indirectly. In practice, this means the timing rules for your thyroid tablet matter more once you start Mounjaro, not less. The standard advice is to take levothyroxine first thing in the morning, at least 30 minutes before food or other medicines, and that gap becomes worth protecting carefully.

If your thyroid function has been stable for years and then shifts after starting tirzepatide, it is not necessarily a sign something has gone wrong; it may reflect a change in how consistently your body absorbs levothyroxine. Your GP can check your TSH and adjust your dose if needed. There is a dedicated page exploring Mounjaro and hypothyroidism that goes into the absorption question in more detail. For context on the other end of the spectrum, the picture with hyperthyroidism is quite different.

What is still uncertain, and who decides

Clinical trials of tirzepatide, including the SURMOUNT-1 study published in the New England Journal of Medicine, did not specifically isolate participants with hypothyroidism as a subgroup. That means robust long-term data on this combination is thinner than clinicians would ideally like. It does not mean the combination is unsafe, it means decisions are made on general pharmacological principles and individual assessment rather than a dedicated evidence base.

The question of thyroid cancer risk comes up because GLP-1 receptor agonists caused thyroid C-cell tumours in rodent studies. The NHS and MHRA note this finding while also acknowledging that human relevance has not been established. The NHS tirzepatide information page describes this as a reason for the black triangle monitoring designation, not a reason to refuse treatment to everyone with a thyroid condition.

If your thyroid history is more complex (a previous thyroid cancer (other than medullary), radioiodine treatment, or a thyroid nodule under investigation) tell your prescriber at consultation. Suitability is assessed case by case. A clinical decision cannot be made on diagnosis alone, which is why our prescribers review each consultation individually, with the same-day assessment carried out by a real clinician, not an automated system. The clinical team at nume is well practised in flagging cases that need GP input before proceeding.

Cost and the wider picture

If you are considering Mounjaro and want to understand what private treatment involves financially, the Mounjaro cost page sets out what is included in a legitimate private prescription, consultation, clinical review, dispensing and delivery. People sometimes approach weight management medicines through the NHS first; eligibility criteria there are strict and phased, and those with hypothyroidism still need to meet the standard BMI and comorbidity thresholds. For the private route, the BMI requirements for Mounjaro are a useful starting reference, though BMI alone never determines the outcome of a consultation. Some patients ask about eligibility at lower BMI values too, the position on BMI under 30 is explained separately. For a fuller picture of tirzepatide as a treatment, the Mounjaro overview covers mechanism, results and practical detail in one place.